Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naive prostate cancer cells.

ABSTRACT: Anti-androgen therapy with Enzalutamide (Enz) has been used as a therapy for castration resistant prostate cancer (CRPC) patients after development of resistance to chemotherapy with Docetaxel (Doc). The potential impacts of Doc-chemotherapy on the subsequent Enz treatment, however, remain unclear. Here we found the overall survival rate of patients that received Enz was significantly less in patients that received prior Doc-chemotherapy than those who had not. In vitro studies from 3 established Doc resistant CRPC (DocRPC) cell lines are consistent with the clinical findings showing DocRPC patients had decreased Enz-sensitivity as well as accelerated development of Enz-resistance via enhanced androgen receptor (AR) splicing variant 7 (ARv7) expression. Mechanism dissection f

SUBMITTER: Lin C 

PROVIDER: S-EPMC7521536 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature